Polycythemia Vera Market is expected to Reach ~USD 5,600 million by 2036

The total Polycythemia Vera (PV) market size in the 7MM was approximately ~USD 2,000 million in 2025 and is projected to increase during the forecast period (2026–2036), reaching an estimated ~USD 5,600 million by 2036 at a CAGR of 8.9%. DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Polycythemia Vera landscape.

In 2025, the Polycythemia Vera market size was highest in the United States among the 7MM, accounting for approximately ~USD 1,500 million, which is further expected to increase by 2036, owing to the launch of emerging therapies, assisted by an increase in the diagnosed prevalent population of Polycythemia Vera.

Most Polycythemia Vera patients are symptomatic, with approximately ~91,000 patients carrying the JAK2 mutation in the United States in 2025. Ruxolitinib (JAKAFI) and ropeginterferon alfa-2b (BESREMi) are approved across the US, Europe, and Japan, with ruxolitinib established as a standard second-line therapy since 2015, while BESREMi's broader label spans both first and subsequent lines of therapy. JAKAFI's patent expiration in mid-2028 stands as a significant obstacle to its market supremacy, prompting Incyte's LIMBER life-cycle management initiative to explore monotherapy and combination approaches beyond ruxolitinib.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The United States contributed the largest prevalent population of Polycythemia Vera, acquiring ~55% of the 7MM in 2025, whereas EU4 and the UK, and Japan accounted for around ~30% and ~15% of the total population share, respectively. The total number of prevalent cases of Polycythemia Vera in the United States was around ~158,700 cases in 2025, comprising roughly ~63,000 asymptomatic and ~95,000 symptomatic cases. Among the EU4 and the UK, Germany accounted for the largest number of Polycythemia Vera cases based on symptoms, whereas the UK accounted for the lowest number of cases in 2025. In Japan, the age-specific data revealed that the highest number of affected people was found in the 65–74 years age group, with ~6,000 cases in 2025, while the 0–34 years age group was the least affected, with ~800 cases. Across the 7MM, approximately ~60% of the patient share is attributed to males, whereas only ~40% of females suffer from Polycythemia Vera.

DelveInsight's report, "Polycythemia Vera Market Insights, Epidemiology and Market Forecast – 2036," provides a comprehensive analysis of the Polycythemia Vera landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Polycythemia Vera market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here — Polycythemia Vera Market Forecast

Key Facts of the Polycythemia Vera Market Report

• 2025 Polycythemia Vera Market Size (7MM): ~USD 2,000 million 2036 Projected Polycythemia Vera Market Size (7MM): ~USD 5,600 million Polycythemia Vera Growth Rate (2026–2036): 8.9% CAGR
• Key Polycythemia Vera Companies: Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, and others
• Key Polycythemia Vera Therapies: Ruxolitinib (JAKAFI/JAKAVI), Ropeginterferon alfa-2b (BESREMi), Rusfertide, Bomedemstat, Givinostat (DUVYZAT), Sapablursen (TMPRSS6), Divesiran (SLN124), PPMX-T003, 9MW3011/DISC-3405, and others
• The Polycythemia Vera market is expected to grow due to the disease's rising prevalence, improved diagnostic technologies, and growing awareness during the forecast period. Furthermore, the launch of multiple emerging therapies across various stages of development will significantly influence the Polycythemia Vera market dynamics.

Polycythemia Vera Overview

Polycythemia Vera is a rare condition characterized by the progressively increased number of red blood cells in the bloodstream; white blood cells (WBC) and platelets also increase in number in affected people. Polycythemia Vera is the most common myeloproliferative neoplasm (MPN) and the only one in which there is an increase in RBC production. It usually occurs at an elderly age, and patients are at higher risk of thrombotic events and other comorbidities.

Diagnosis is based on results from tests assessing elevations in blood counts and the presence of molecular mutations associated with the disease, including a focused clinical history, physical examination, hematocrit concentration, RBC/WBC/platelet counts, serum EPO level, and cytogenetic abnormalities, most commonly following WHO criteria based on JAK2 mutation status and serum erythropoietin level.

Treatment centers on phlebotomy to maintain safe hematocrit levels, often combined with low-dose aspirin, with high-risk patients receiving cytoreductive therapy such as hydroxycarbamide (hydroxyurea). JAKAFI and BESREMi are the two FDA-approved drugs for treating Polycythemia Vera, though approximately 30% of hydroxyurea-treated patients become resistant or intolerant, underscoring the continued need for additional treatment options.

Get a free sample for the Polycythemia Vera Market Report: https://www.delveinsight.com/report-store/polycythemia-vera-market

Key Trends in Polycythemia Vera Therapeutics Market

• Rising Prevalence of Polycythemia Vera: Increasing diagnosis among the aging population, particularly individuals over age 60, continues to expand the patient pool and fuel demand for diagnostics and long-term treatment.
• Advancements in Diagnostic Technologies: Genetic testing for JAK2 mutations and improved blood profiling techniques are enabling more accurate, timely diagnosis and earlier treatment initiation.
• Emergence of Targeted Therapies: JAK inhibitors and other mechanism-targeted therapies are transforming the treatment landscape, offering better efficacy and outcomes than traditional cytoreductive agents.
• Growing Focus on Personalized Medicine: Therapies tailored to individual genetic profiles and disease characteristics are gaining traction, improving effectiveness and patient compliance.
• Expanding Therapeutic Pipeline: A strong pipeline of interferons, monoclonal antibodies, hepcidin mimetics, and novel small molecules is set to expand treatment options for hydroxyurea-resistant patients.
• Shift Toward Innovative Treatment Modalities: RNA-based therapies and advanced biologics offering less frequent dosing and better tolerability are gaining attention for improving patient adherence.

Polycythemia Vera Epidemiology

Key findings from Polycythemia Vera epidemiological analysis and forecast highlight the disease's prevalence, incidence, and patient demographics across the 7MM, including gender-, age-, mutation-, and risk-based segmentation, helping stakeholders understand the scope of the disease and plan targeted interventions, research, and treatment strategies.

Polycythemia Vera Epidemiology Segmentation

The Polycythemia Vera market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM, segmented into:

• Total Prevalent Population of Polycythemia Vera
• Prevalent Population of Polycythemia Vera Based on Symptoms
• Gender-specific Prevalence of Polycythemia Vera
• Prevalence of Polycythemia Vera by Gene Mutation
• Prevalence of Polycythemia Vera Based on Risk
• Age-specific Prevalence of Polycythemia Vera

Download the report to understand which factors are driving Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast

Recent Developments in the Polycythemia Vera Treatment Landscape

• In June 2026: PharmaEssentia USA Corporation announced U.S. FDA approval and commercial launch of the BESREMi Pen (ropeginterferon alfa-2b-njft), a subcutaneous injection device designed to provide a more streamlined and accurate self-administration experience for adults with polycythemia vera.
• In June 2026: Protagonist Therapeutics announced four clinical abstract presentations for rusfertide at the European Hematology Association (EHA) Congress, featuring safety and efficacy subgroup analyses from the pivotal Phase 3 VERIFY trial and long-term outcomes from the Phase 2 REVIVE and THRIVE open-label extension studies.
• In June 2026: Deciphera Pharmaceuticals dosed the first patient in its global Phase 3 INTREPID trial evaluating sapablursen, an investigational RNAi therapeutic targeting the TMPRSS6 gene to restore iron balance and reduce phlebotomy requirements in polycythemia vera patients.
• In May 2026: PharmaEssentia Corporation announced it would present Phase 3 SURPASS-ET trial data for ropeginterferon alfa-2b at ASCO and EHA, evaluating the therapy in high-risk essential thrombocythemia patients who previously failed hydroxyurea treatment.
• In May 2026: The U.S. FDA approved Incyte's Jakafi XR (ruxolitinib extended-release) tablets for intermediate- or high-risk myelofibrosis, polycythemia vera, and graft-versus-host disease, offering a once-daily dosing alternative to the immediate-release version.
• In January 2026: Takeda Pharmaceuticals and Protagonist Therapeutics submitted a New Drug Application to the U.S. FDA for rusfertide, supported by favorable 52-week data from the global Phase 3 VERIFY trial showing effective hematocrit control and reduced need for therapeutic phlebotomy.
• In August 2025: Vanda announced that the FDA had granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of Polycythemia Vera.
• In December 2024: The American Society of Hematology (ASH) Annual Meeting featured research on the long-term safety and efficacy of ruxolitinib for polycythemia vera patients, highlighting its superiority over hydroxyurea and reduced reliance on corticosteroids.

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential Polycythemia Vera drugs expected to be launched during 2022–2036. For rusfertide, although the FDA rescinded its Breakthrough Designation, uptake is expected to be medium-fast, with a probability-adjusted peak share of 5.7% in the first and second lines, and years to peak expected at 7 years from launch.

The report also covers Polycythemia Vera Pipeline Development Activities, providing valuable insights about therapeutic candidates in various stages and the key companies involved in developing targeted treatments, along with recent developments such as collaborations, acquisitions, mergers, and licensing patent details.

Polycythemia Vera Approved and Emerging Therapies

• Ruxolitinib (JAKAFI/JAKAVI): Incyte/Novartis
• Ropeginterferon alfa-2b (BESREMi): PharmaEssentia/AOP Orphan Pharmaceuticals
• Peginterferon alfa-2a (PEGASYS): Pharma and GmbH
• Rusfertide (PTG-300): Protagonist Therapeutics/Takeda Pharmaceuticals
• Bomedemstat: Merck (Imago BioSciences)
• Sapablursen (TMPRSS6 inhibitor): Ionis Pharmaceuticals/Ono Pharmaceutical
• Divesiran (SLN124): Silence Therapeutics
• PPMX-T003 (anti-TfR1): Perseus Proteomics
• DISC-3405 (anti-TMPRSS6): Disc Medicine
• Givinostat (DUVYZAT): Italfarmaco
• GLB-001: Hangzhou GluBio Pharmaceutical
• INCB160058: Incyte
• AG-236: Agios Pharmaceuticals/Alnylam Pharmaceuticals
• VGT-1849A / VGT-1849B: Vanda Pharmaceuticals
• JAK2V617F: Prelude Therapeutics/Incyte
• PN-8047: Protagonist Therapeutics

In 2025, among current therapies, the largest revenue was generated by JAKAFI, at approximately ~USD 1,000 million in the United States. By 2036, among emerging therapies in the EU4 and the UK, the highest revenue is expected to be generated by Rusfertide.

To know more about Polycythemia Vera companies working in the treatment market, visit @ Polycythemia Vera Clinical Trials and Therapeutic Assessment

Polycythemia Vera Market Drivers

• Rising prevalence of Polycythemia Vera, particularly among the aging population over age 60, expanding the patient pool
• Increasing awareness and early diagnosis driven by educational initiatives and patient advocacy
• Advancements in diagnostic technologies, including JAK2 genetic testing and improved blood profiling
• Emergence of targeted therapies, particularly JAK inhibitors, addressing underlying molecular mechanisms
• Growing focus on personalized and precision medicine tailored to individual genetic profiles
• Robust R&D activity and an expanding therapeutic pipeline of interferons, monoclonal antibodies, and novel small molecules
• Favorable healthcare policies and reimbursement support facilitating patient access to advanced therapies
• Increasing demand for long-term disease management, as Polycythemia Vera remains a chronic condition with no definitive cure

Polycythemia Vera Market Barriers

• Ongoing disease burden due to poor rates of sustained hematocrit (Hct) control
• Psychosocial and access challenges linked to the disease's rarity and low awareness
• Delayed diagnosis despite established criteria and clear treatment triggers
• Deterioration in quality of life driven by treatment burden and persistent symptoms
• Limited third-line treatment options, with approximately 30% of hydroxyurea-treated patients becoming resistant or intolerant
• Access and reimbursement issues for off-label therapies such as PEGASYS prior to formal approval

Scope of the Polycythemia Vera Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage : Global
• Key Polycythemia Vera Companies: Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, and others
• Key Polycythemia Vera Therapies: Ruxolitinib (JAKAFI/JAKAVI), Ropeginterferon alfa-2b (BESREMi), Rusfertide, Bomedemstat, Givinostat (DUVYZAT), Sapablursen (TMPRSS6), Divesiran (SLN124), PPMX-T003, 9MW3011/DISC-3405, and others
• Polycythemia Vera Market Segmented By: Region/geographies, drugs/therapies
• Analysis Covered: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet need, market drivers and barriers, epidemiology patient burden

Discover more about therapies set to grab major Polycythemia Vera market share @ Polycythemia Vera Treatment Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.